Literature DB >> 23321182

Response to nonsteroidal anti-inflammatory drugs in African Americans with osteoarthritis of the knee.

M N Essex1, M O'Connell, P Bhadra Brown.   

Abstract

OBJECTIVE: This 6-week, randomized, double-blind, parallel-group study compared the analgesic efficacy, tolerability and safety of celecoxib, naproxen and placebo in African Americans with osteoarthritis (OA) of the knee.
METHODS: A total of 322 patients aged ≥ 45 years with OA of the knee in a flare state received 200 mg celecoxib orally once daily, 500 mg naproxen orally twice daily or placebo for 6 weeks. The primary endpoint was change from baseline in the Patient's Assessment of Arthritis Pain.
RESULTS: Celecoxib was as effective as naproxen in reducing OA pain. Similar efficacy was observed in many of the secondary outcome measures. Celecoxib was well tolerated and demonstrated favorable upper gastro-intestinal tolerability. Improvements in outcome measures were numerically greater in the active treatment groups compared with the placebo group, but did not reach statistical significance.
CONCLUSIONS: Celecoxib was as effective as naproxen in relieving OA pain in African Americans and was well tolerated. Few significant differences were observed between active treatments and placebo, possibly because of a strong placebo effect.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23321182     DOI: 10.1177/030006051204000623

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  9 in total

Review 1.  Celecoxib for osteoarthritis.

Authors:  Livia Puljak; Ana Marin; Davorka Vrdoljak; Filipa Markotic; Ana Utrobicic; Peter Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2017-05-22

2.  Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study.

Authors:  Margaret N Essex; Michael A O'Connell; Regina Behar; Weihang Bao
Journal:  Int J Rheum Dis       Date:  2015-05-20       Impact factor: 2.454

3.  Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder.

Authors:  Ken O'Reilly; Gary Donohoe; Danny O'Sullivan; Ciaran Coyle; Ronan Mullaney; Paul O'Connell; Catherine Maddock; Andrea Nulty; Padraic O'Flynn; Carina O'Connell; Harry G Kennedy
Journal:  BMC Psychiatry       Date:  2016-01-13       Impact factor: 3.630

4.  Comparing the Safety and Efficacy of Celecoxib for the Treatment of Osteoarthritis in Asian and non-Asian Populations: An Analysis of Data from Two Randomized, Double-blind, Placebo-controlled, Active-comparator Trials.

Authors:  Andri Lubis; Wei Wang; Graça Lima; Rana Fayyad; Chris Walker
Journal:  Pain Ther       Date:  2017-09-18

5.  Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.

Authors:  Elizabeth Curtis; Nicholas Fuggle; Sarah Shaw; Laura Spooner; Georgia Ntani; Camille Parsons; Nadia Corp; Germain Honvo; Janis Baird; Stefania Maggi; Elaine Dennison; Olivier Bruyère; Jean-Yves Reginster; Cyrus Cooper
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

Review 6.  Recent advances in the synthesis of fluorinated hydrazones.

Authors:  Rui Guo; Junting Chen
Journal:  RSC Adv       Date:  2018-05-10       Impact factor: 3.361

7.  Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis.

Authors:  Margaret Noyes Essex; Regina Behar; Michael A O'Connell; Pritha Bhadra Brown
Journal:  Int J Gen Med       Date:  2014-05-16

8.  Defining acute flares in knee osteoarthritis: a systematic review.

Authors:  Emma L Parry; Martin J Thomas; George Peat
Journal:  BMJ Open       Date:  2018-07-19       Impact factor: 2.692

9.  Work-related outcomes in randomized, double blind, placebo-controlled trials in osteoarthritis - are they adequately reported in journal publications? A systematic review.

Authors:  Daniel Sowah; Flora Balat; Sebastian Straube
Journal:  J Occup Med Toxicol       Date:  2018-10-20       Impact factor: 2.646

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.